Danish health officials the European Medicines Agency’s (EMA) that “there is a possible link between rare but severe cases of blood clots and the COVID-19 vaccine from J&J,” referring to an investigation last month into eight U.S. reports of rare blood clots — one of which was fatal — that occurred after recent vaccination.
Unlike the Danish Health Authority however, the EMA the benefits of using the J&J vaccine outweigh the risks. The EMA did recommend adding a warning to J&J’s vaccine label, and the company said it would comply with that measure.
“Taking the present situation in Denmark into account, what we are currently losing in our effort to prevent severe illness from COVID-19 cannot outweigh the risk of causing possible side effects in the form of severe blood clots in those we vaccinate,” the health authority said.
Scientists in Norway and Germany who studied blood clots after vaccination with AstraZeneca some people may experience an abnormal immune response causing them to form antibodies that attack their own platelets after being vaccinated.
On April 13, the Centers for Disease Control and Prevent (CDC) and the U.S. Food and Drug Administration (FDA) to the use of J&J’s COVID vaccine, marketed under the company’s Janssen subsidiary, while they investigated at least six cases of potentially dangerous blood clots in people who received the vaccine. All six occurred in women between the ages of 18 and 48, and symptoms occurred six to 13 days after vaccination. One death was reported.
On April 14, the CDC’s Advisory Committee on Immunization Practices (ACIP) postponed a vote on whether to lift the pause on the J&J vaccine, effectively pending further analysis of data relating to blood clots in people who received the vaccine.
On April 23, the ACIP voted 10 – 4 to of the J&J shot without restrictions or an additional warning about the risk of blood clotting disorders after analyzing 15 cases of rare blood clots, including three deaths, according to a shared during the meeting.
The ACIP said the link between blood clots and J&J’s COVID vaccine was “plausible,” but concluded the vaccine’s benefits outweigh the risks and recommended the vaccine for persons 18 years of age and older in the U.S. under the FDA’s (EUA).
queried the for a series of adverse events associated with the formation of clotting disorders and other related conditions. VAERS yielded a total of for all three vaccines from Dec. 14, 2020, through April 23.
Though J&J and AstraZeneca vaccines have been under the microscope for their potential to cause blood clots, , as far back as December 2020, that mRNA vaccines like Pfizer and Moderna pose similar risks.